trial

3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals

NCTId NCT02220504
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 68 (actual)
Sponsored by Fundación Marques de Valdecilla
Primary completion 2014-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
68 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2004-07
Primary completion
2014-02
Eligibility
ALL · 15 Years · 60 Years

Interventions & indications

Drugs
Antipsychotic treatment discontinuationAripiprazole

Sponsors

Fundación Marques de ValdecillaLead Sponsor
Centro de Investigación Biomédica en Red de Salud MentalCollaborator
Instituto de Investigación Marqués de ValdecillaCollaborator

Investigators

1
Benedicto Crespo-Facorro, ProfessorPrincipal Investigator

Sites

1 total
Santander, Spain

Facts & assertions

4 sourced
Enrollment
68
Phase
NA
Primary Completion Date
2014-02
Status
COMPLETED
relationships
The graph out of here
drug
Antipsychotic treatment discontinuation
drug
Aripiprazole
drug
lead_sponsor
Fundación Marques de Valdecilla
company
collaborator
Centro de Investigación Biomédica en Red de Salud Mental
company
Instituto de Investigación Marqués de Valdecilla
company
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia
indication
investigator
Benedicto Crespo-Facorro, Professor
person